Literature DB >> 27664254

appendix 6: Chronic lymphocytic leukaemia: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Haematological-Malignancies).

B Eichhorst1, T Robak2, E Montserrat3, P Ghia4, P Hillmen5, M Hallek6, C Buske7.   

Abstract

Entities:  

Year:  2016        PMID： 27664254     DOI： 10.1093/annonc/mdw359

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  8 in total

1.  Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL).

Authors:  Francesca Romana Mauro; Diana Giannarelli; Clementina Maria Galluzzo; Candida Vitale; Andrea Visentin; Costantino Riemma; Serena Rosati; Marika Porrazzo; Sara Pepe; Marta Coscia; Livio Trentin; Massimo Gentile; Sara Raponi; Alessandra Micozzi; Giuseppe Gentile; Silvia Baroncelli
Journal:  Leukemia       Date:  2020-06-17       Impact factor: 11.528

Review 2.  Current Treatment of Chronic Lymphocytic Leukemia.

Authors:  Krzysztof Jamroziak; Bartosz Puła; Jan Walewski
Journal:  Curr Treat Options Oncol       Date:  2017-01

Review 3.  Chronic lymphocytic leukaemia.

Authors:  Thomas J Kipps; Freda K Stevenson; Catherine J Wu; Carlo M Croce; Graham Packham; William G Wierda; Susan O'Brien; John Gribben; Kanti Rai
Journal:  Nat Rev Dis Primers       Date:  2017-01-19       Impact factor: 52.329

4.  Comparative Efficacy of Ibrutinib Versus Obinutuzumab + Chlorambucil in First-Line Treatment of Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison.

Authors:  Suzy Van Sanden; Simona Baculea; Joris Diels; Sarah Cote
Journal:  Adv Ther       Date:  2017-06-01       Impact factor: 3.845

5.  HIF-1α is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia.

Authors:  Valentina Griggio; Candida Vitale; Maria Todaro; Chiara Riganti; Joanna Kopecka; Chiara Salvetti; Riccardo Bomben; Michele Dal Bo; Daniela Magliulo; Davide Rossi; Gabriele Pozzato; Lisa Bonello; Monia Marchetti; Paola Omedè; Ahad Ahmed Kodipad; Luca Laurenti; Giovanni Del Poeta; Francesca Romana Mauro; Rosa Bernardi; Thorsten Zenz; Valter Gattei; Gianluca Gaidano; Robin Foà; Massimo Massaia; Mario Boccadoro; Marta Coscia
Journal:  Haematologica       Date:  2019-07-09       Impact factor: 9.941

6.  Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk.

Authors:  Markus C Stühlinger; Ansgar Weltermann; Philipp Staber; Daniel Heintel; Thomas Nösslinger; Michael Steurer
Journal:  Wien Klin Wochenschr       Date:  2019-08-14       Impact factor: 1.704

Review 7.  Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia.

Authors:  Bartosz Puła; Aleksandra Gołos; Patryk Górniak; Krzysztof Jamroziak
Journal:  Cancers (Basel)       Date:  2019-11-21       Impact factor: 6.639

8.  Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.

Authors:  Alexander Egle; Michael Steurer; Thomas Melchardt; Lukas Weiss; Franz Josef Gassner; Nadja Zaborsky; Roland Geisberger; Kemal Catakovic; Tanja Nicole Hartmann; Lisa Pleyer; Daniela Voskova; Josef Thaler; Alois Lang; Michael Girschikofsky; Andreas Petzer; Richard Greil
Journal:  Ann Hematol       Date:  2018-06-04       Impact factor: 3.673
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.